Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 10 studies | 24% ± 7% | |
macrophage | 7 studies | 25% ± 8% | |
astrocyte | 6 studies | 31% ± 15% | |
glutamatergic neuron | 6 studies | 51% ± 24% | |
microglial cell | 6 studies | 46% ± 13% | |
myeloid cell | 5 studies | 32% ± 9% | |
epithelial cell | 5 studies | 29% ± 9% | |
GABAergic neuron | 5 studies | 43% ± 19% | |
oligodendrocyte | 5 studies | 27% ± 8% | |
oligodendrocyte precursor cell | 5 studies | 31% ± 12% | |
retinal ganglion cell | 4 studies | 26% ± 9% | |
retina horizontal cell | 4 studies | 21% ± 4% | |
retinal rod cell | 4 studies | 19% ± 1% | |
dendritic cell | 4 studies | 26% ± 9% | |
pericyte | 4 studies | 19% ± 2% | |
interneuron | 4 studies | 47% ± 23% | |
classical monocyte | 3 studies | 23% ± 3% | |
conventional dendritic cell | 3 studies | 23% ± 7% | |
retinal bipolar neuron | 3 studies | 22% ± 2% | |
retinal cone cell | 3 studies | 29% ± 7% | |
mononuclear phagocyte | 3 studies | 25% ± 7% | |
ciliated cell | 3 studies | 21% ± 1% | |
lymphocyte | 3 studies | 18% ± 1% | |
Mueller cell | 3 studies | 19% ± 1% | |
glycinergic amacrine cell | 3 studies | 19% ± 1% | |
monocyte | 3 studies | 20% ± 4% | |
smooth muscle cell | 3 studies | 21% ± 4% | |
plasmacytoid dendritic cell | 3 studies | 23% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1777.46 | 1445 / 1445 | 100% | 13.90 | 183 / 183 |
lung | 100% | 2304.49 | 578 / 578 | 100% | 16.37 | 1155 / 1155 |
breast | 100% | 1966.03 | 459 / 459 | 100% | 18.58 | 1117 / 1118 |
prostate | 100% | 1797.51 | 245 / 245 | 100% | 13.48 | 501 / 502 |
brain | 100% | 2090.11 | 2641 / 2642 | 100% | 12.37 | 703 / 705 |
ovary | 100% | 1760.06 | 180 / 180 | 100% | 12.29 | 428 / 430 |
uterus | 100% | 1808.39 | 170 / 170 | 99% | 11.76 | 455 / 459 |
thymus | 100% | 1721.19 | 653 / 653 | 99% | 12.19 | 599 / 605 |
pancreas | 100% | 1064.66 | 328 / 328 | 98% | 10.77 | 175 / 178 |
kidney | 100% | 1762.74 | 89 / 89 | 98% | 12.19 | 885 / 901 |
stomach | 100% | 1299.67 | 359 / 359 | 98% | 11.10 | 279 / 286 |
bladder | 100% | 1837.81 | 21 / 21 | 97% | 11.26 | 491 / 504 |
intestine | 100% | 1589.09 | 966 / 966 | 97% | 9.99 | 509 / 527 |
adrenal gland | 100% | 1760.03 | 258 / 258 | 96% | 11.11 | 221 / 230 |
liver | 100% | 1186.18 | 226 / 226 | 96% | 7.45 | 390 / 406 |
skin | 100% | 1586.12 | 1807 / 1809 | 92% | 10.85 | 432 / 472 |
blood vessel | 100% | 2247.00 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 1859.46 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2043.78 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 11.10 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 8.08 | 1 / 1 |
adipose | 100% | 2132.71 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 99% | 1261.23 | 850 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 1813.97 | 902 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 7.00 | 28 / 29 |
eye | 0% | 0 | 0 / 0 | 69% | 7.37 | 55 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006281 | Biological process | DNA repair |
GO_0006515 | Biological process | protein quality control for misfolded or incompletely synthesized proteins |
GO_0006513 | Biological process | protein monoubiquitination |
GO_0070979 | Biological process | protein K11-linked ubiquitination |
GO_0071218 | Biological process | cellular response to misfolded protein |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0140374 | Biological process | antiviral innate immune response |
GO_1904262 | Biological process | negative regulation of TORC1 signaling |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0061631 | Molecular function | ubiquitin conjugating enzyme activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005515 | Molecular function | protein binding |
GO_0005524 | Molecular function | ATP binding |
Gene name | UBE2W |
Protein name | Ubiquitin conjugating enzyme E2 W N-terminal E2 ubiquitin-conjugating enzyme (EC 2.3.2.23) (EC 2.3.2.25) Ubiquitin-conjugating enzyme E2 W (EC 2.3.2.23) (E2 ubiquitin-conjugating enzyme W) (N-terminal E2 ubiquitin-conjugating enzyme) (EC 2.3.2.25) (N-terminus-conjugating E2) (Ubiquitin carrier protein W) (Ubiquitin-conjugating enzyme 16) (UBC-16) (Ubiquitin-protein ligase W) |
Synonyms | UBC16 |
Description | FUNCTION: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins . Specifically monoubiquitinates the N-terminus of various substrates, including ATXN3, MAPT/TAU, POLR2H/RPB8 and STUB1/CHIP, by recognizing backbone atoms of disordered N-termini . Involved in degradation of misfolded chaperone substrates by mediating monoubiquitination of STUB1/CHIP, leading to recruitment of ATXN3 to monoubiquitinated STUB1/CHIP, and restriction of the length of ubiquitin chain attached to STUB1/CHIP substrates by ATXN3. After UV irradiation, but not after mitomycin-C (MMC) treatment, acts as a specific E2 ubiquitin-conjugating enzyme for the Fanconi anemia complex by associating with E3 ubiquitin-protein ligase FANCL and catalyzing monoubiquitination of FANCD2, a key step in the DNA damage pathway . In vitro catalyzes 'Lys-11'-linked polyubiquitination. UBE2W-catalyzed ubiquitination occurs also in the presence of inactive RING/U-box type E3s, i.e. lacking the active site cysteine residues to form thioester bonds with ubiquitin, or even in the absence of E3, albeit at a slower rate . . |
Accessions | ENST00000517608.5 [Q96B02-3] ENST00000523278.5 E5RG25 X6REH9 ENST00000519255.2 Q96FI0 H0YB73 ENST00000602593.6 [Q96B02-1] ENST00000651945.1 [Q96B02-2] ENST00000422906.6 Q96B02 ENST00000419880.7 ENST00000519277.5 ENST00000650817.1 |